Daniel Delorme

SONIA 2001 : Take II

Martin Paré, Benoît Châtelain, Benoit Gervais-Laurendeau, 2001 .

Discovery of N-(2-aminophenyl)-4-[(4-pyridin-3-ylpyrimidin-2-ylamino)methyl]benzamide (MGCD0103), an orally active histone deacetylase inhibitor.

Isabelle Paquin, Daniel Delorme, A. Kalita, 2008, Journal of medicinal chemistry.

Novel hydroxamate and anilide derivatives as potent histone deacetylase inhibitors: synthesis and antiproliferative evaluation.

Daniel Delorme, G. Bouchain, D. Delorme, 2003, Current medicinal chemistry.

MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo

Sylvain Lefebvre, Daniel Delorme, A. Kalita, 2008, Molecular Cancer Therapeutics.

SYNTHESIS AND BIOLOGICAL EVALUATION OF BOTH ENANTIOMERS OF L-761,000 AS INHIBITORS OF CYCLOOXYGENASE 1 AND 2

Yves Leblanc, Daniel Guay, Petpiboon Prasit, 1996 .

Structurally simple trichostatin A-like straight chain hydroxamates as potent histone deacetylase inhibitors.

Daniel Delorme, O. Moradei, S. Leit, 2002, Journal of medicinal chemistry.

Development of potential antitumor agents. Synthesis and biological evaluation of a new set of sulfonamide derivatives as histone deacetylase inhibitors.

Daniel Delorme, A. Kalita, M. Robert, 2003, Journal of medicinal chemistry.